I Peace: Funding, Investors & Team (Sep 2026)

I Peace is a cell and gene therapy CDMO specializing in iPSC-derived cell products. We provide cGMP cells/iPSCs and contract manufacturing services for medical use globally. The company was founded in 2015 by Koji Tanabe, a graduate of Professor Shinya Yamanaka's lab at Kyoto University and the second author of the paper that reported the world's first successful establishment of human iPS cells. Tanabe, who has been involved in iPS cell research since the beginning of its development, is committed to making iPS cells accessible to all people through I Peace. I Peace’s unique technology enables the parallel production of multiple donor-derived iPS cells without contamination concerns and makes it possible to provide a large number of iPS cells at a reasonable cost. I Peace supports drug discovery and cell therapy development through the use of the iPS cell and other cell products that meet PMDA and FDA standards as high-quality cell products for pharmaceutical and cell therapy companies, and also promotes the production of iPS cells for individuals so that each and every person in the world can prepare for the future by possessing his or her own iPS cells. In addition to supporting pharmaceutical and cell therapy companies so that cell therapy will be within the reach of patients as soon as possible, I Peace aims to spread regenerative cell therapy as soon as possible by establishing iPS cell banking services for individuals.

I Peace has raised $8.5M across 1 round on record. The most recent is an undisclosed round of $8.5M announced in Nov 2024.

I Peace's most recent funding round on record is an undisclosed round of $8.5M, announced in Nov 2024.

FundedIQ lists Koji Tanabe (Founder) at I Peace.

I Peace is based in Palo Alto, California, United States.

I Peace is in the 11-50 employee band.

I Peace's latest round of $8.5M is in line with the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.